Nature Communications (Feb 2021)
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma
- Ziad Bakouny,
- David A. Braun,
- Sachet A. Shukla,
- Wenting Pan,
- Xin Gao,
- Yue Hou,
- Abdallah Flaifel,
- Stephen Tang,
- Alice Bosma-Moody,
- Meng Xiao He,
- Natalie Vokes,
- Jackson Nyman,
- Wanling Xie,
- Amin H. Nassar,
- Sarah Abou Alaiwi,
- Ronan Flippot,
- Gabrielle Bouchard,
- John A. Steinharter,
- Pier Vitale Nuzzo,
- Miriam Ficial,
- Miriam Sant’Angelo,
- Juliet Forman,
- Jacob E. Berchuck,
- Shaan Dudani,
- Kevin Bi,
- Jihye Park,
- Sabrina Camp,
- Maura Sticco-Ivins,
- Laure Hirsch,
- Sylvan C. Baca,
- Megan Wind-Rotolo,
- Petra Ross-Macdonald,
- Maxine Sun,
- Gwo-Shu Mary Lee,
- Steven L. Chang,
- Xiao X. Wei,
- Bradley A. McGregor,
- Lauren C. Harshman,
- Giannicola Genovese,
- Leigh Ellis,
- Mark Pomerantz,
- Michelle S. Hirsch,
- Matthew L. Freedman,
- Michael B. Atkins,
- Catherine J. Wu,
- Thai H. Ho,
- W. Marston Linehan,
- David F. McDermott,
- Daniel Y. C. Heng,
- Srinivas R. Viswanathan,
- Sabina Signoretti,
- Eliezer M. Van Allen,
- Toni K. Choueiri
Affiliations
- Ziad Bakouny
- Department of Medical Oncology, Dana-Farber Cancer Institute
- David A. Braun
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Sachet A. Shukla
- Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute
- Wenting Pan
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Xin Gao
- Department of Medicine, Massachusetts General Hospital Cancer Center
- Yue Hou
- Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute
- Abdallah Flaifel
- Department of Pathology, Brigham and Women’s Hospital
- Stephen Tang
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Alice Bosma-Moody
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Meng Xiao He
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Natalie Vokes
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Jackson Nyman
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Wanling Xie
- Department of Data Sciences, Dana-Farber Cancer Institute
- Amin H. Nassar
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Sarah Abou Alaiwi
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Ronan Flippot
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Gabrielle Bouchard
- Department of Medical Oncology, Dana-Farber Cancer Institute
- John A. Steinharter
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Pier Vitale Nuzzo
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Miriam Ficial
- Department of Pathology, Brigham and Women’s Hospital
- Miriam Sant’Angelo
- Department of Pathology, Brigham and Women’s Hospital
- Juliet Forman
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Jacob E. Berchuck
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Shaan Dudani
- Tom Baker Cancer Centre, University of Calgary
- Kevin Bi
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Jihye Park
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Sabrina Camp
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Maura Sticco-Ivins
- Department of Pathology, Brigham and Women’s Hospital
- Laure Hirsch
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Sylvan C. Baca
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Megan Wind-Rotolo
- Bristol-Myers Squibb
- Petra Ross-Macdonald
- Bristol-Myers Squibb
- Maxine Sun
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Gwo-Shu Mary Lee
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Steven L. Chang
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Xiao X. Wei
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Bradley A. McGregor
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Lauren C. Harshman
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Giannicola Genovese
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
- Leigh Ellis
- Department of Pathology, Brigham and Women’s Hospital
- Mark Pomerantz
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Michelle S. Hirsch
- Department of Pathology, Brigham and Women’s Hospital
- Matthew L. Freedman
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Michael B. Atkins
- Lombardi Comprehensive Cancer Center, Georgetown University Medical Center
- Catherine J. Wu
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Thai H. Ho
- Division of Hematology and Medical Oncology, Mayo Clinic
- W. Marston Linehan
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH
- David F. McDermott
- Beth Israel Deaconess Medical Center
- Daniel Y. C. Heng
- Tom Baker Cancer Centre, University of Calgary
- Srinivas R. Viswanathan
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Sabina Signoretti
- Department of Pathology, Brigham and Women’s Hospital
- Eliezer M. Van Allen
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Toni K. Choueiri
- Department of Medical Oncology, Dana-Farber Cancer Institute
- DOI
- https://doi.org/10.1038/s41467-021-21068-9
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 14
Abstract
Sarcomatoid and rhabdoid tumours are highly aggressive forms of renal cell carcinoma that are also responsive to immunotherapy. In this study, the authors perform a comprehensive molecular characterization of these tumours discovering an enrichment of specific alterations and an inflamed phenotype.
